QIAGEN N.V.

QGEN

Held by 1 specialist biotech fund

Fund Holdings

AI Signal

RA Capital's $2.1M initiation in QIAGEN suggests conviction in molecular diagnostics consolidation or upcoming PCR/sequencing revenue inflection.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 43,976Value: $2.1M

RA Capital's $2.1M initiation in QIAGEN suggests conviction in molecular diagnostics consolidation or upcoming PCR/sequencing revenue inflection. QIAGEN's core oncology and infectious disease panels face near-term headwinds from declining COVID testing, but the position sizing implies confidence in either M&A optionality or non-COVID diagnostic growth acceleration in 2024-2025.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SLDB1 fund SION1 fund SPRY1 fund ABOS1 fund TSHA1 fund PCSC1 fund RNA1 fund VOR1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: